ArticleOncoTargets and therapy2018

Low-dose hypomethylating agent decitabine in combination with aclacinomycin and cytarabine achieves a better outcome than standard FLAG chemotherapy in refractory/relapsed acute myeloid leukemia patients with poor-risk cytogenetics and mutations.

Limin Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.